Latest Biotech Startup Funding Rounds
Financing for drug discovery, therapeutics and biological technologies, with the development context behind each round.
- Rounds
- 470 Jan 1 – Oct 24, 2026
- Disclosed funding
- $19.5B 399 disclosed amounts
- Median round
- $20M Of disclosed amounts
| Company | Amount | Round | Sector | Country | Investors | Announced |
|---|---|---|---|---|---|---|
| S SableCompany profile Develops high-performance topical solutions for body contouring and sustained aesthetic results Develops high-performance topical solutions for body contouring and sustained aesthetic results | Undisclosed | Pre-SeedPre-seed | Biotech | United States | Investors | |
| TM Transition Metal SolutionsCompany profile Develops custom chemical additives to enhance wild microbial communities for metal extraction Develops custom chemical additives to enhance wild microbial communities for metal extraction | $6M | Seed | Biotech, Industrial tech | United States | Investors | |
| CT Caldera TherapeuticsCompany profile Develops bispecific antibody CLD-423 for inflammatory bowel disease Develops bispecific antibody CLD-423 for inflammatory bowel disease | $37.5M | Series A1Series A | Biotech | United States | Investors | |
| RL Develops AI operating system for oncology workflows | $11.1M | Series A | Biotech, AI | United States | Investors | |
| AB Provider of human induced pluripotent stem cell (iPSC) technologies | $2.8M | Undisclosed | Biotech | United Kingdom | Investors | |
| VO Vivere OncotherapiesCompany profile Vivere Oncotherapies develops cancer treatments designed to activate immune recognition and destruction of cancer cells. Vivere Oncotherapies develops cancer treatments designed to activate immune recognition and destruction of cancer cells. | $10M | Series A | Biotech | United States | Investors | |
| N NucleraCompany profile Provides rapid access to functional proteins through benchtop eProtein Discovery System Provides rapid access to functional proteins through benchtop eProtein Discovery System | $12M | Series C+ | Biotech | United Kingdom | Investors | |
| S Provides enterprise informatics platform for laboratories | Undisclosed | Undisclosed | Biotech, Enterprise software | United States | Investors | |
| CB AI platform for accelerated drug discovery and development | $25M | Series A | Biotech, AI | United States | Investors | |
| P Develops AI-driven drug discovery for proximity therapeutics | $80M | Undisclosed | Biotech | United States | Investors |
Active investors in this selection
All investors →Ranked by rounds participated in · From Jan 1, 2026
- 1RA Capital Management
Estuary Biotherapeutics, Circle Pharma, Inc., Solstice Oncology
22rounds3led - 2Janus Henderson Investors
Star Therapeutics, OMass Therapeutics, Soufflé Therapeutics
15rounds1led - 3Eli Lilly and Company
BigHat Biosciences, Circle Pharma, Inc., Moonwalk Biosciences
15rounds0led - 4ARCH Venture Partners
Soufflé Therapeutics, Encoded Therapeutics Inc., Moonwalk Biosciences
14rounds0led - 5OrbiMed
Star Therapeutics, Leal Therapeutics, Accro Bioscience
11rounds1led
Latest digests
Archive →Explore published rounds while the next edition is being prepared.